sap114 Antibody

What is SAP114 and what cellular functions does it perform?

SAP114, also known as spliceosome-associated protein 114, PRP21, PRPF21, SF3A120, or SF3A1, is a 793 amino acid nuclear protein that belongs to the SURP protein family. It is characterized by two SURP motif repeats and one ubiquitin-like domain. SAP114 is ubiquitously expressed across mammalian tissues and plays a critical role in pre-mRNA splicing as a subunit of the SF3A splicing factor complex . This complex is essential for binding U2 small nuclear ribonucleoprotein (snRNP) to the branchpoint sequence in pre-mRNA. The SF3A complex converts 15S U2 snRNP into the active 17S form, which is directly involved in pre-mRNA splicing events. Within this complex, SAP114 serves as the first subunit, interacting with subunit 2 (SAP 62) and subunit 3 (SAP 61) through SURP motifs . These interactions facilitate E complex assembly, which regulates cell cycle progression from G1 phase into S phase in mammalian cells, underscoring SAP114's importance in gene expression regulation and cellular function .

What types of SAP114 antibodies are commercially available for research?

The research community has access to several types of SAP114/SF3A1 antibodies optimized for different experimental applications. Mouse monoclonal antibodies like SAP 114 Antibody (H-10) detect SAP 114 protein across mouse, rat, and human samples . These are available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates to accommodate diverse experimental needs . Additionally, rabbit recombinant monoclonal antibodies like Anti-SF3A1 [EPR7666] target the same protein with high specificity . There are also rabbit polyclonal antibodies available, with some specifically targeting the N-terminal region of the protein . These antibodies have been validated for various applications including western blotting (WB), immunoprecipitation (IP), immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA) .

How does SAP114's protein structure relate to its splicing function?

SAP114's functionality in pre-mRNA splicing derives from its specific structural domains. The protein contains two SURP motif repeats and one ubiquitin-like domain, which are characteristic of the SURP protein family . These structural elements are critical for SAP114's role as a subunit of the SF3A splicing factor complex. As a component of the 17S U2 SnRNP complex, SAP114/SF3A1 directly participates in early spliceosome assembly and mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing . The SURP motifs specifically enable SAP114 to interact with other SF3A complex components, particularly subunit 2 (SAP 62) and subunit 3 (SAP 61) . This interaction facilitates the assembly of the pre-spliceosome 'E' complex and the pre-catalytic spliceosome 'A' complex . Further research has shown SAP114 is also involved in pre-mRNA splicing as a component of pre-catalytic spliceosome 'B' complexes, highlighting its extensive involvement throughout the splicing process .

What are the optimal protocols for using SAP114 antibodies in Western blotting?

When using SAP114 antibodies for Western blotting, researchers should follow specific methodological approaches to ensure optimal results. First, protein extraction should be performed using nuclear extraction protocols, as SAP114 is predominantly localized in the nucleus . Standard protein lysate preparation with RIPA buffer containing protease inhibitors is recommended. For gel electrophoresis, 10-20 μg of total protein should be loaded per lane on a 6-8% SDS-PAGE gel (due to SAP114's large molecular weight of approximately 120 kDa) .

During transfer to nitrocellulose or PVDF membranes, extended transfer times (90-120 minutes) at lower voltage settings are recommended for efficient transfer of this large protein. For immunodetection, the following protocol typically yields optimal results:

• Block membranes with 5% non-fat dry milk in TBST for 60 minutes at room temperature

• Incubate with primary SAP114 antibody (recommended dilution 1:500-1:1000 for mouse monoclonal or rabbit polyclonal antibodies) overnight at 4°C

• Wash 3-5 times with TBST, 5 minutes each

• Incubate with appropriate HRP-conjugated secondary antibody (1:2000-1:5000) for 1 hour at room temperature

• Wash 3-5 times with TBST, 5 minutes each

• Develop using enhanced chemiluminescence (ECL)

Expected results include a clear band at approximately 120 kDa, though precise molecular weight may vary slightly between species .

How should researchers optimize SAP114 antibody-based immunoprecipitation experiments?

For successful immunoprecipitation (IP) of SAP114, researchers should implement a carefully optimized protocol that considers the protein's nuclear localization and its role in protein complexes. Begin by preparing nuclear extracts from cells of interest using a gentle lysis buffer (e.g., 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40) supplemented with protease inhibitors and phosphatase inhibitors . The following step-by-step methodology is recommended:

• Pre-clear 500-1000 μg of nuclear extract with protein A/G beads for 1 hour at 4°C to reduce non-specific binding

• Incubate pre-cleared lysate with 2-5 μg of SAP114 antibody (H-10 mouse monoclonal or equivalent) overnight at 4°C with gentle rotation

• Add 40 μl protein A/G beads and incubate for 4 hours at 4°C

• Wash immunoprecipitates 4-5 times with wash buffer (lysis buffer with reduced detergent concentration)

• Elute proteins by boiling in 2× SDS sample buffer for 5 minutes

This approach effectively pulls down SAP114 along with its interaction partners in the SF3A complex, namely SAP62 and SAP61 . For co-immunoprecipitation studies investigating splicing complex components, salt concentration should be kept at physiological levels to maintain protein-protein interactions. Western blotting can then be used to confirm the presence of SAP114 and associated proteins in the immunoprecipitates.

What are the recommended protocols for immunofluorescence studies with SAP114 antibodies?

Immunofluorescence (IF) using SAP114 antibodies can provide valuable insights into the subcellular localization and distribution patterns of this splicing factor. For optimal results, researchers should follow this protocol:

• Culture cells on sterile coverslips to 60-80% confluence

• Fix cells with 4% paraformaldehyde in PBS for 15 minutes at room temperature

• Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes

• Block with 3% BSA in PBS for 1 hour at room temperature

• Incubate with primary SAP114 antibody diluted 1:100-1:200 in blocking solution overnight at 4°C

• Wash 3× with PBS, 5 minutes each

• Incubate with fluorophore-conjugated secondary antibody (1:500) for 1 hour at room temperature in the dark

• Wash 3× with PBS, 5 minutes each

• Counterstain nuclei with DAPI (1 μg/ml) for 5 minutes

• Mount using anti-fade mounting medium

Expected results show predominantly nuclear staining with a speckled pattern characteristic of splicing factors . For co-localization studies with other spliceosome components, a sequential or simultaneous dual-staining approach can be employed, depending on the primary antibody host species. Using confocal microscopy with z-stack acquisition is recommended for optimal visualization of nuclear speckle patterns.

How can SAP114 antibodies be used to study spliceosome assembly dynamics?

SAP114 antibodies offer powerful tools for investigating the dynamic assembly of spliceosomes during pre-mRNA processing. For studying these complex dynamics, researchers can implement chromatin immunoprecipitation (ChIP) assays with SAP114 antibodies to map the temporal and spatial recruitment of the SF3A complex to specific pre-mRNA transcripts . This approach requires crosslinking cellular components with formaldehyde, followed by immunoprecipitation with SAP114 antibodies, and finally analyzing the associated pre-mRNA sequences.

For real-time visualization of spliceosome assembly, immunofluorescence combined with RNA FISH (Fluorescence In Situ Hybridization) can reveal the co-localization of SAP114 with specific RNA transcripts. This dual-labeling strategy provides insights into where and when splicing factors engage with target transcripts .

Researchers investigating the kinetics of spliceosome assembly can employ proximity ligation assays (PLA) using SAP114 antibodies in combination with antibodies against other spliceosome components. This technique can visualize and quantify protein-protein interactions at specific timepoints during splicing events, revealing the sequential assembly process of the E, A, and B complexes in which SAP114 participates .

For more detailed mechanistic studies, SAP114 antibodies can be used in splicing inhibition experiments, where antibody-mediated depletion or blocking of SAP114 from nuclear extracts will disrupt the assembly of the 17S U2 snRNP complex, enabling researchers to assess downstream effects on splicing efficiency and accuracy .

What role does SAP114 play in alternative splicing, and how can antibodies help investigate this process?

SAP114/SF3A1, as a core component of the U2 snRNP, plays a critical role in alternative splicing decisions through its involvement in branch point recognition and spliceosome assembly. Researchers investigating alternative splicing can use SAP114 antibodies in several sophisticated approaches.

RNA immunoprecipitation followed by sequencing (RIP-seq) using SAP114 antibodies allows researchers to identify the RNA targets that directly interact with the SF3A complex . This approach can reveal preferential binding to specific types of alternative exons or intronic regions, providing insights into how SAP114 influences splice site selection.

For studying SAP114's role in cell-type specific or condition-dependent alternative splicing, researchers can use immunofluorescence with SAP114 antibodies combined with RNA-seq analysis across different cellular contexts. Changes in SAP114 localization patterns often correlate with shifts in alternative splicing profiles .

Mechanistically, IP-mass spectrometry experiments using SAP114 antibodies can identify differential protein partners that associate with the SF3A complex under various conditions, potentially explaining context-dependent effects on alternative splicing . These protein interaction networks may reveal auxiliary factors that modulate SAP114's function at specific splice sites.

In disease models where splicing is dysregulated, comparative analysis of SAP114 expression, localization, and interaction partners (using the antibodies for WB, IF, and IP respectively) can provide valuable insights into pathological mechanisms involving aberrant splicing events .

How can researchers use SAP114 antibodies to investigate its role in cell cycle regulation?

SAP114's involvement in cell cycle regulation, particularly in the transition from G1 to S phase, can be investigated using strategic applications of SAP114 antibodies. Flow cytometry analysis combined with SAP114 immunostaining can be used to correlate SAP114 expression levels with cell cycle phases, revealing potential fluctuations in protein abundance throughout the cell cycle .

For mechanistic studies, researchers can employ chromatin immunoprecipitation followed by sequencing (ChIP-seq) with SAP114 antibodies to identify cell cycle-regulated genes whose splicing is directly modulated by SAP114. This approach can reveal target genes involved in G1/S transition that require proper splicing mediated by the SF3A complex .

To investigate phosphorylation-dependent regulation of SAP114 during the cell cycle, immunoprecipitation with SAP114 antibodies followed by phospho-specific Western blotting or mass spectrometry can reveal post-translational modifications that might regulate its activity at specific cell cycle stages .

For functional studies, researchers can perform synchronized cell experiments where SAP114 is depleted (using siRNA) and then reintroduced (detected using SAP114 antibodies) at specific cell cycle stages to determine the precise temporal windows during which SAP114 function is critical for cell cycle progression .

What are common challenges when using SAP114 antibodies, and how can they be addressed?

When working with SAP114 antibodies, researchers may encounter several technical challenges that require specific solutions. One common issue is weak signal in Western blots, which can be addressed by optimizing protein extraction to ensure efficient nuclear protein recovery (using specialized nuclear extraction kits) and increasing protein loading to 25-30 μg per lane . Extending primary antibody incubation time to 16-24 hours at 4°C and using enhanced chemiluminescence substrates designed for low-abundance proteins can also improve sensitivity.

High background in immunofluorescence experiments is another frequent challenge. This can be minimized by increasing blocking time (2-3 hours), using more stringent washing conditions (0.1% Tween-20 in PBS, 5-6 washes), and diluting the primary antibody in solutions containing 1-5% normal serum from the species of the secondary antibody .

For immunoprecipitation experiments, researchers may experience non-specific pull-down. This can be addressed by increasing pre-clearing time with protein A/G beads (2-3 hours), using more stringent wash buffers for immunoprecipitates, and validating results with multiple antibodies targeting different epitopes of SAP114 .

Cross-reactivity with other SURP family proteins can be evaluated by performing control experiments with recombinant proteins or cell lines with CRISPR-mediated knockout of SAP114. Using highly specific monoclonal antibodies like H-10 can minimize cross-reactivity issues .

How should researchers validate and interpret SAP114 antibody specificity in their experimental systems?

Proper validation of SAP114 antibody specificity is critical for reliable experimental outcomes. Researchers should implement a multi-faceted validation approach that includes several strategies. Western blot validation should demonstrate a single band at the expected molecular weight (~120 kDa) in positive control samples (HeLa or HEK293 cell lysates) and absence of this band when the protein is knocked down using siRNA or CRISPR-Cas9 technologies .

For immunofluorescence validation, co-staining with antibodies against other known splicing factors (e.g., SC35, U2AF65) should show co-localization in nuclear speckles. Additionally, the staining pattern should be diminished in cells where SAP114 expression has been reduced through genetic manipulation .

Peptide competition assays, where the antibody is pre-incubated with excess SAP114 antigenic peptide, should abolish specific signals in all applications, confirming binding specificity . Cross-validation with multiple antibodies targeting different epitopes of SAP114 is recommended to confirm consistent results across different antibody clones .

When interpreting results, researchers should consider species-specific variations in SAP114 expression and localization patterns. Human, mouse, and rat SAP114 share high homology, but subtle differences may affect antibody reactivity and experimental outcomes . The expression level of SAP114 can also vary between cell types and physiological conditions, which should be considered when interpreting intensity differences.

What data analysis approaches are recommended for quantitative studies using SAP114 antibodies?

For quantitative analysis of SAP114 expression or localization using antibody-based techniques, researchers should employ rigorous data analysis approaches to ensure reliable and reproducible results. In Western blot quantification, researchers should normalize SAP114 signal intensity to multiple housekeeping controls (e.g., GAPDH, β-actin, and a nuclear protein like Lamin B1) to account for both loading variations and nuclear extraction efficiency .

When analyzing immunofluorescence data, quantitative image analysis should be performed using specialized software (ImageJ, CellProfiler) with standardized parameters. Nuclear speckle analysis requires 3D confocal z-stacks rather than single plane images to accurately capture the complete distribution pattern of this splicing factor .

The following table presents recommended normalization approaches for different experimental techniques:

For time-course experiments tracking SAP114 dynamics, researchers should employ time-series analysis methods such as curve fitting or area-under-curve calculations rather than single timepoint comparisons . When correlating SAP114 levels with functional outcomes (e.g., splicing efficiency, cell cycle progression), regression analysis with appropriate controls for confounding variables should be performed.

How are SAP114 antibodies being used in cancer research and potential therapeutic development?

SAP114/SF3A1 antibodies are becoming increasingly valuable tools in cancer research due to the emerging recognition of splicing dysregulation as a hallmark of many malignancies. Researchers are employing these antibodies to analyze SAP114 expression patterns across cancer types using tissue microarrays and immunohistochemistry, revealing potential correlations between aberrant SAP114 expression and disease progression or prognosis .

In mechanistic studies, SAP114 antibodies are used in combination with RNA-seq analyses to identify cancer-specific alternative splicing events that depend on SAP114 function. This approach has revealed that certain oncogenes and tumor suppressors undergo alternative splicing mediated by the SF3A complex, suggesting SAP114 as a potential upstream regulator of cancer-related gene expression .

Researchers developing splicing-targeted cancer therapeutics use SAP114 antibodies to evaluate compound effects on spliceosome assembly and composition. In drug screening platforms, these antibodies help monitor SAP114 localization, complex formation, and functional activity following treatment with splicing modulators, providing mechanistic insights into drug action .

Interestingly, the self-assembled proteomimetic (SAP) technology mentioned in the search results represents a new approach for developing antibody-like binding molecules that could potentially target components of the splicing machinery, including SAP114, opening new avenues for therapeutic intervention in cancers with splicing aberrations .

How can SAP114 antibodies contribute to understanding neurodegenerative disease mechanisms?

Emerging research suggests that pre-mRNA splicing dysregulation plays a significant role in various neurodegenerative disorders. SAP114 antibodies provide valuable tools for investigating these connections. In post-mortem brain tissue studies, researchers use these antibodies for immunohistochemical analysis to detect abnormal localization or aggregation of SAP114 in affected neurons, which may indicate disruption of normal splicing processes in diseases such as Alzheimer's and Parkinson's .

SAP114 antibodies can be employed in co-immunoprecipitation experiments to identify disease-specific alterations in spliceosome composition or interactome changes in cellular and animal models of neurodegeneration. This approach can reveal how pathological protein aggregates (like tau or α-synuclein) might interfere with SAP114 function and spliceosome assembly .

In functional studies, researchers use SAP114 antibodies to monitor the integrity of nuclear speckles—sites of splicing factor concentration—in response to cellular stressors associated with neurodegeneration, such as oxidative stress, protein misfolding, or excitotoxicity. Disruption of these structures, as detected by immunofluorescence with SAP114 antibodies, often precedes neuronal dysfunction .

The methodological approach for such studies typically involves dual immunofluorescence labeling with SAP114 antibodies and markers of neurodegeneration, combined with high-resolution confocal or super-resolution microscopy to detect subtle changes in splicing factor distribution that might contribute to disease pathogenesis.